osimertinib - Globe Thesis

Keyword [osimertinib] Result: 41 - 60 \| Page: 3 of 4
41.	Clinical Observation Of 64 Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutation Treated With Osimertinib
42.	The Clinical Efficacy And Safety Analysis Of Osimertinib Combined With Brain Radiation Therapy On Non-Small Cell Lung Cancer With Brain Metastases
43.	The Role Of Osimertinib Combined With PD0332991 In EGFR-TKIs Resistant Lung Cancer Cells
44.	Osimertinib For EGFR-mutant Lung Cancer With Central Nervous System Metastases:A Meta-analysis And Systematic
45.	Real World Efficacy And Resistance Mechanism Of Osimertinib And CAR-T Cell Therapy For EGFR Mutant NSCLC Patients
46.	HK2 Regulates The Resistance Of Osimertinib In Lung Adenocarcinoma By Inhibiting The Degradation Of EGFR Ubiquitination
47.	Treatment Of Advanced EGFR-mutant Non-small-cell Lung Cancer:A Single-center Experience
48.	Mechanisms Of Ferroptosis In Drug Resistance Of Esophageal Squamous Cell Carcinoma And Effects Of DSG2 In Drug Resistance Of Lung Adenocarcinoma
49.	Molecular Mechanism Of Osimertinib Resistance Induced By EGFR L792F Mutation And PTPRD As A Biomarker For Immunotherapy In NSCLC
50.	Mechanism Of Targeting YAP1 Increased DUSP1 To Reverse Osimertinib Resistance In Non-Small Cell Lung Cancer
51.	Tumor Microenvironment Changes After Osimertinib Resistance And Potential Management In NSCLC
52.	Application Of Anti-angiogenic Drug Combination Therapy In Non-small Cell Lung Cancer And Exploration Of Circulating Tumor DNA Based Prognostic Biomarkers In Small Cell Lung Cancer
53.	The Effects And Mechanisms Of KDM6B In Acquired Resistance To EGFR Tyrosine Kinase Inhibitors In Lung Adenocarcinoma
54.	Effect And Mechanism Of BCL-2 In Resistance To Third Generation EGFR-TKI In Lung Adenocarcinoma
55.	Study On The New Mechanism Of Acquired Resistance To The Third-generation EGFR-TKI Osimertinib And Its Treatment Strateg
56.	Efficacy And Safety Of Osimertinib In The Treatment Of Advanced Non-small Cell Lung Cancer With EGFR T790M Mutation
57.	The Association Between BIM Deletion And Therapeutic Efficacy Of Osimertinib、PD-1/PD-L1 Inhibitors In NSCLC
58.	Research On The Potential Cardiotoxic Effect And Mechanism Of Osimertinib
59.	Curcumin And Osimertinib Synergistically Inhibit The Proliferation And Migration Of Osimertinib-Resistant Non-Small Cell Lung Cancer Cells Through Ferroptosis
60.	Expression And Clinical Significance Of Th1/Th2/Th17 Cytokines And Lymphocyte Subsets In PCNSL
<<First <Prev Next> Last>> Jump to